If you run a pharma business in India and have not read the Torrent-JB Chemicals deal announcement carefully, you should. Not because it is a pharma story. Because it is the clearest public data point we have had in years on what your business is actually worth — and what it would be worth if you spent five years preparing it properly before a sale.
Torrent Pharmaceuticals paid 24.8× EBITDA for JB Chemicals in June 2025. KKR had bought the same business in 2020 for roughly Rs. 3,100 Cr. Five years. Eight times the entry price. No new drugs invented. No new markets entered. No company rebuilt from scratch.
Most coverage treated this as a pharma consolidation story. It is actually a business preparation story — and the gap it reveals between what founder-owned pharma businesses sell for today and what they could sell for with the right preparation is the most important number in Indian mid-market M&A right now.
What Pharma Business Valuation in India Actually Looks Like
underprepared
institutional
2025
The current market prices founder-owned pharma businesses in the Rs. 50 to 500 Cr revenue range at 6 to 8× EBITDA. PE-backed assets with institutional governance and professional management trade at 18 to 24×. That is not a sector difference. Both pools sit in the same therapeutic categories, the same geographies, the same regulatory environment.
The difference is diligence-readiness. What a buyer finds when they open the data room determines where in that range your business prices. A promoter-owned business where the P&L carries personal expenses, where customer concentration is undocumented, where the MD is the only relationship the company has with its top three distributors: that business prices at the bottom of the range, if it closes at all.
JB Chemicals under the Mody family: Rs. 2,800 Cr revenue, EBITDA margins of 15–18%. Under KKR: 18% revenue CAGR, margins of 27–29%, Rs. 7–7.5 billion in annual free cash flow. Same assets. Different preparation. Three times the multiple.
Five Decisions That Created Rs. 22,000 Crore of Exit Value
KKR did not run a complicated playbook. They made five decisions over five years — each replicable at a fraction of the scale by any founder thinking about exit in the next five to seven years.
Separate ownership from management on day one. KKR appointed Nikhil Chopra as CEO within weeks — a 24-year Cipla veteran. The Mody family exited operations immediately and cleanly. An acquirer will not pay 20× for a business that stops working when the promoter steps back.
Run a consistent bolt-on acquisition strategy. Five bolt-on acquisitions in four years, each receiving the same operating playbook. Sporlac grew 34% post-acquisition. Razel grew 33%. JB Chemicals moved from 28th to 21st in the Indian pharma market. Platforms command platform multiples.
Fund the capability the promoter had been ignoring. The CDMO arm — medicated lozenges with global potential — was 11% of revenue when KKR arrived, starved of capital. By FY25 it generated Rs. 446 Cr annually with global leadership in a USD 4.6 billion segment. Every founder-owned pharma business has a version of this.
Improve the economics without changing the business. EBITDA margins nearly doubled — from 15–18% to a guided 27–29% — through supply chain optimisation and product mix discipline, not price increases. The business funded four acquisitions and stayed nearly debt-free.
Build governance so any buyer can understand the business quickly. An institutional board, credentialed independent directors, and an audit trail rebuilt to diligence standards. When Torrent arrived at the data room, there were no structural surprises. In Indian mid-market pharma, that is rarer than it sounds.
Why the Next 24 Months Are an Unusual Window
Revised Schedule M became binding on January 1, 2026. Tier 3 manufacturers who cannot fund the upgrades are approaching advisors now — not distressed, but unable to wait out another market cycle.
ChrysCapital's Rs. 1,300 Cr acquisition of 71% of Novartis India in Q1 2026 confirmed institutional buyers are not on the sidelines. The Torrent-JB deal sets the ceiling multiple.
Second-generation families across the Rs. 50–300 Cr pharma segment are facing a question the first generation never had to answer: does this business need to stay in the family?
What a Valuation-Ready Pharma Business Looks Like
The preparation that separates a 6× exit from an 18× exit is not capital-intensive. Most of it is decisions, not investment.
Governance & Documentation
- At least one credentialed independent director before any formal process
- Clean separation of company vs. promoter personal expenses in the P&L
- All key customer and distributor relationships documented and transferable
- Regulatory compliance current and auditable: GMP, Schedule M, GST/ITR/EPF/ESI
- Three years of audited financials with no unexplained adjustments
- EBITDA reconciliation a buyer's CFO can verify without the promoter
Management & Strategy
- A second layer that can run the business without the promoter for 90 days
- Customer concentration quantified: top five customers, contract terms, renewal history
- One identified dormant capability with a documented investment thesis
- Clear answer to: why would a strategic buyer pay more than a financial buyer?
None of this requires hiring an investment bank today. It requires 12 to 24 months of deliberate preparation. The promoters who do that work now will price at the top of the range the Torrent-JB deal has just established. Those who do not will price at the floor — or not at all.
The Risks This Deal Creates
The Torrent-JB deal will cause some buyers to overpay for pharma assets on the assumption that every founder-owned business contains hidden upside of the same type. It does not. The CDMO vertical at JB Chemicals was genuinely underinvested — a specific set of conditions that does not exist in every mid-market acquisition.
For sellers, the risk is timing. The Schedule M compliance window and the current PE deployment cycle are creating motivated but non-distressed seller conditions. Those conditions will not persist indefinitely. A founder who treats this as a signal to begin preparation is thinking correctly. One who waits until distress forces the decision will find the window has closed.
Founder-owned businesses in the Rs. 50–500 Cr range typically sell at 6–8× EBITDA. PE-backed assets with institutional governance trade at 18–24×. The Torrent-JB Chemicals deal at 24.8× is the current ceiling for institutionally prepared assets in Indian mid-market pharma.
Meaningful preparation typically requires 18–36 months. Priority items: professional management layer, clean P&L, documented customer relationships, resolved governance gaps, and funding any dormant capability. Businesses that begin 24 months before an intended sale will have significantly more options at exit.
Five moves over five years: appointed a professional CEO, ran a consistent bolt-on strategy across five targets, funded a dormant CDMO capability that grew to Rs. 446 Cr, improved EBITDA margins from 15–18% to 27–29%, and rebuilt governance to institutional diligence standards.
A motivated seller approaches the market by choice, with time and options. A distressed seller approaches because an external pressure — a compliance deadline, a succession crisis — has removed optionality. Motivated sellers price at the top of the range; distressed sellers price at the bottom.
For businesses in the Rs. 50–300 Cr range, a boutique M&A advisory firm with Indian mid-market pharma experience will typically be more effective than a large investment bank. The advisor's most important work happens in the 18–24 months before any sale process — not during it.
Thinking about an exit in the next two to five years? The right time to talk is before you engage a bank.
Begin the Conversation